Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for OptimizeRx (OPRX) over the last 13 years, with Q3 2025 value amounting to -$258000.0.

  • OptimizeRx's Cash from Financing Activities rose 5150.38% to -$258000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year decrease of 11771.18%. This contributed to the annual value of -$4.9 million for FY2024, which is 11740.26% down from last year.
  • OptimizeRx's Cash from Financing Activities amounted to -$258000.0 in Q3 2025, which was up 5150.38% from -$4.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Cash from Financing Activities ranged from a high of $70.2 million in Q1 2021 and a low of -$12.0 million during Q3 2022
  • Over the past 5 years, OptimizeRx's median Cash from Financing Activities value was -$348000.0 (recorded in 2023), while the average stood at $3.8 million.
  • Per our database at Business Quant, OptimizeRx's Cash from Financing Activities skyrocketed by 6247644.45% in 2021 and then tumbled by 308059.63% in 2023.
  • Quarter analysis of 5 years shows OptimizeRx's Cash from Financing Activities stood at $1.1 million in 2021, then crashed by 802.65% to -$7.4 million in 2022, then soared by 586.46% to $36.2 million in 2023, then tumbled by 107.8% to -$2.8 million in 2024, then surged by 90.86% to -$258000.0 in 2025.
  • Its last three reported values are -$258000.0 in Q3 2025, -$4.5 million for Q2 2025, and -$587000.0 during Q1 2025.